A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

BD Provides Update on Previously Disclosed Recall of BD Alaris System Hardware

BD today provided an update on a previously announced voluntary recall of the BD Alaris™ System.

Alaris System: Three of the situations described in this recall, which BD announced on June 30, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. One of the situations was designated as a Class II recall, which means use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

This FDA classification does not change the guidance BD provided in the company’s June recall announcement to customers.

BD initiated the voluntary recall to notify customers of the potential for four hardware situations that may result in the infusion pump not operating as expected. BD has provided instructions to correct and/or mitigate the situations. The four situations include:

  1. Damaged Inter-Unit Interface (IUI) Connectors (Situation 1 – Class I)
  2. Broken elements on Alaris™ Pump Module platen (Situation 2 – Class I)
  3. Improperly secured PC unit Battery (Situation 3 – Class I)
  4. Dim LED Segment(s) on the Alaris™ modules (Situation 4 – Class II)

Customers should review and follow the instructions in the recall letter: www.bd.com/en-us/support/recall-notifications/recall-notification-for-alaris-system-infusion-pump-hardware

Affected Products

Product Name

Situation 1

Situation 2

Situation 3*

Situation 4

Alaris™ System PC Unit Model 8000

X

X

Alaris™ System PC Unit Model 8015

X

X

X

Alaris™ Pump Module Model 8100

X

X

X

Alaris™ Syringe Module Model 8110

X

X

Alaris™ PCA Module Model 8120

X

X

Alaris™ EtCO2 Module Model 8300

X

X

Alaris™ SpO2 Module Model 8210 and Model 8220

X

X

Alaris™ Auto ID Module Model 8600

X

*Note: Since Situation 3 affects the batteries of the PC Units, it may cause power loss to any attached module.

Note that some affected devices may be branded under the CareFusion name. Customer inquiries related to this action should be addressed to BD’s Recall Support Center at 888-562-6018 or SupportCenter@bd.com.

FDA MedWatch Reporting

Adverse reactions/events experienced with the use of either of these products should also be reported to the FDA’s MedWatch Program by:

  • Web: MedWatch website at www.fda.gov/medwatch
  • Phone: 1-800-FDA-1088
  • Fax: 1-800-FDA-0178
  • Mail: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787
SourceBD
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy